Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.450
-0.040 (-1.61%)
At close: Jul 16, 2026, 4:00 PM EDT
2.350
-0.100 (-4.08%)
Pre-market: Jul 17, 2026, 5:41 AM EDT
Ovid Therapeutics Revenue
Ovid Therapeutics had revenue of $7.12M in the twelve months ending March 31, 2026, up 1,199.64% year-over-year. In the year 2025, Ovid Therapeutics had annual revenue of $7.25M with 1,181.27% growth.
Revenue (ttm)
$7.12M
Revenue Growth
+1,199.64%
P/S Ratio
64.21
Revenue / Employee
$309,652
Employees
23
Market Cap
457.27M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.25M | 6.69M | 1,181.27% |
| Dec 31, 2024 | 566.00K | 174.00K | 44.39% |
| Dec 31, 2023 | 392.00K | -1.11M | -73.91% |
| Dec 31, 2022 | 1.50M | -206.88M | -99.28% |
| Dec 31, 2021 | 208.38M | 195.77M | 1,551.58% |
| Dec 31, 2020 | 12.62M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 180.25M |
| Prothena Corporation | 57.94M |
| Editas Medicine | 38.69M |
| Adlai Nortye | 5.00M |
| Ocugen | 4.47M |
| Artiva Biotherapeutics | 251.00K |
OVID News
- 9 days ago - Ovid Therapeutics CFO Jeffrey Rona to step down, Charles Carter to succeed - TheFly
- 9 days ago - Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development - GlobeNewsWire
- 4 weeks ago - Ovid Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 5 weeks ago - Ovid Therapeutics Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Ovid Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors - GlobeNewsWire
- 2 months ago - Ovid Therapeutics price target raised to $7 from $5 at Roth Capital - TheFly
- 2 months ago - Ovid Therapeutics reports Q1 EPS (12c), consensus (11c) - TheFly